financetom
Business
financetom
/
Business
/
Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue
Nov 3, 2024 3:44 PM

10:24 AM EDT, 10/31/2024 (MT Newswires) -- Kymera Therapeutics ( KYMR ) shares were down over 1% in recent Thursday trading after the company reported a Q3 loss, while its collaboration revenue decreased year-over-year and fell short of analyst expectations.

The company reported a Q3 net loss of $0.82 per diluted share, compared with a loss of $0.90 a year earlier.

Analysts polled by Capital IQ expected a $0.84 loss.

Collaboration revenue for the quarter ended Sept. 30 fell to $3.7 million from $4.7 million a year earlier.

Analysts surveyed by Capital IQ expected $10.3 million.

In August, the company raised about $247 million in net proceeds from an equity offering. Kymera said Thursday it extended its cash runway into mid-2027 with the proceeds.

Price: 46.97, Change: -0.70, Percent Change: -1.47

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved